Skip to search formSkip to main contentSkip to account menu

ciprokiren

Known as: (alphaS)-N-((1S,2R,3S)-1-(Cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)-alpha-((alphaS)-alpha-(((1-methyl-1-(morpholinocarbonyl)ethyl)sulfonyl)methyl)hydrocinnamamido)imidazole-4-propionamide, 1H-Imidazole-4-propanamide, N-(1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)-alpha-((2-(((1,1-dimethyl-2-(4-morpholinyl)-2-oxoethyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, (1S-(1R*(R*(R*)),2S*,3R*))- 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Imidazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Renal vascular and biochemical responses to systemic renin inhibition in dogs at low renal perfusion pressure.
Renin is produced by the kidney and secreted into the systemic circulation. However, its biochemical and physiological role of… 
1998
1998
Preserved vasodilator effect of bradykinin in dogs with heart failure.
BACKGROUND In heart failure (HF), vasoconstrictor systems are activated and endothelium-derived vasodilation is blunted… 
1996
1996
Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure.
To determine the role of the renin-angiotensin system and the bradykinin pathway in the mechanism of action of angiotensin… 
1995
1995
Acute hemodynamic effects of ciprokiren, a novel renin inhibitor, in sodium-depleted dogs.
We evaluated the acute hemodynamic effects of ciprokiren (Ro 44-9375), a new potent renin inhibitor, in sodium-depleted dogs… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)